This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of the TrialNet consortium is to develop clinical trials of treatments that protect pancreatic -cell function, in individuals who are at risk for developing T1D or who have newly diagnosed T1D. Optimal design and completion of these trials depends upon knowledge of the natural history of T1D and effective strategies to recruit subjects. The goals of the TrialNet Natural History Study of the Development of Type 1 Diabetes are to gain information about the natural history and pathogenesis of T1D and to facilitate the recruitment and assessment of individuals who might qualify for T1D prevention trials. The TrialNet Natural History Study of the Development of T1D is divided into three phases: Phase 1 Screening, Phase 2 Baseline Risk Assessment, and Phase 3 Follow-Up Risk Assessment.
Showing the most recent 10 out of 642 publications